The Effect of Gepirone-ER in the Treatment of Sexual Dysfunction in Depressed Men

Journal of Sexual Medicine

Volumn 9, Issue 3, 2012, Pages 821-829

  Fabre, Louis F ^a   Clayton, Anita H ^b   Smith, Louis C ^a   Goldstein, Irwin ^c   Derogatis, Leonard R ^d  

^a Fabre Kramer Pharmaceuticals   (United States)

^b UNIVERSITY OF VIRGINIA   (United States)

^c ALVARADO HOSPITAL   (United States)

^d SHEPPARD PRATT HEALTH SYSTEM   (United States)

Author keywords

DSM IV Diagnoses of Sexual Disorders; Gepirone ER; HSDD; Hypoactive Sexual Desire Disorder; Treatment of Depression and Sexual Dysfunction

Indexed keywords

FLUOXETINE; GEPIRONE;

ADULT; ARTICLE; CONTROLLED STUDY; DEPRESSION; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG WITHDRAWAL; HAMILTON SCALE; HUMAN; INSOMNIA; MAJOR CLINICAL STUDY; MALE; NAUSEA; ORGASM; PRIORITY JOURNAL; SEXUAL AROUSAL; SEXUAL DYSFUNCTION; SEXUAL FUNCTION; SOMNOLENCE; SYNCOPE; TRANQUILIZING ACTIVITY; TREATMENT RESPONSE; VOMITING;

EID: 84863394383     PISSN: 17436095     EISSN: 17436109     Source Type: Journal    
DOI: 10.1111/j.1743-6109.2011.02624.x     Document Type: Article

References (39)

1. Mathew RJ, Weinman ML. Sexual dysfunctions in depression. Arch Sex Behav 1982;11:323-8.
2. Williams K, Reynolds MF. Sexual dysfunction in major depression. CNS Spectr 2006;11(suppl 9):19-23.
3. Weissman MM, Kierman GL. Gender and depression. Trends Neurosci 1985;8:416-20.
4. Gregorian RS, Golden KA, Bahce A, Goodman C, Kwong WJ, Khan ZM. Antidepressant-induced sexual dysfunction. Ann Pharmacother 2002;36:1577-89.
5. Fabre LF, Smith LC. Treatment of hypoactive sexual desire disorder (HSDD) often requires concomitant treatment of mood disorders-A role for gepirone-ER. Thirty-sixth Annual Meeting of the Society for Sex Therapy and Research 2011 Abstract.
6. Clayton AH, Pradko JF, Croft HA, Montano CB, Leadbetter RA, Bolden-Watson C, Bass KI, Donahue RM, Jamerson BD, Metz A. Prevalence of sexual dysfunction among newer antidepressants. J Clin Psychiatry 2002;63:357-66.
7. Zemishlany Z, Weizman A. The impact of mental illness on sexual dysfunction. Adv Psychosom Med 2008;29:89-106.
8. Kennedy SH, Eisfeld BS, Dickens SE, Bacchiochi JR, Bagby RM. Antidepressant-induced sexual dysfunction during treatment with moclobemide, paroxetine, sertraline, and venlafaxine. J Clin Psychiatry 2000;61:276-81.
9. Montejo AL, Perahia DG, Spann ME, Wang F, Walker DJ, Yang CR, Detke MJ. Sexual function during long-term duloxetine treatment in patients with recurrent major depressive disorder. J Sex Med 2011;8:773-82.
10. Baldwin DS. Sexual dysfunction associated with antidepressant drugs. Expert Opin Drug Saf 2004;3:457-70.
11. Hayes DJ, Greenshaw AJ. 5-HT receptors and reward-related behaviour: A review. Neurosci Biobehav Rev 2011;35:1419-49.
12. Pfaus JG. Pathways of sexual desire. J Sex Med 2009;6:1506-33.
13. Bishop JR, Moline J, Ellingrod VL, Schultz SK, Clayton AH. Serotonin 2A -1438 G/A and G-protein Beta3 subunit C825T polymorphisms in patients with depression and SSRI-associated sexual side-effects. Neuropsychopharmacology 2006;31:2281-8.
14. 1A) partial agonist in the treatment of major depression. Prog Neuropsychopharmacol Biol Psychiatry 1992;16:271-80.
15. Kennedy S. Flibanserin: Initial evidence of efficacy on sexual dysfunction in patients with major depressive disorder. J Sex Med 2010;7:3449-59.
16. 1A agonists in the treatment of depression? Biol Psychiatry 2003;53:193-203.
17. Robinson DS, Sitsen JM, Gibertini M. A review of the efficacy and tolerability of immediate-release and extended-release formulations of gepirone. Clin Ther 2003;25:1618-33.
18. Wilcox CS, Ferguson JM, Dale JL, Heiser JF. A double-blind trial of low- and high-dose ranges of gepirone-ER compared with placebo in the treatment of depressed outpatients. Psychopharmacol Bull 1996;32:335-42.
19. Keller MB, Ruwe FJ, Janssens CJ, Sitsen JM, Jokinen R, Janczewski J. Relapse prevention with gepirone ER in outpatients with major depression. J Clin Psychopharmacol 2005;25:79-84.
20. Feiger AD, Heister JF, Shrivastava RK, Weiss KJ, Smith WT, Sitsen JMA, Gibertini M. Gepirone extended release: New evidence for efficacy in the treatment of major depressive disorder. J Clin Psychiatry 2003;64:243-9.
21. Bielski RJ, Cunningham L, Horrigan JP, Londborg PD, Smith WT, Weiss K. Gepirone extended-release in the treatment of adult outpatients with major depressive disorder: A double-blind, randomized, placebo-controlled, parallel-group study. J Clin Psychiatry 2008;69:571-7.
22. DeVeaugh-Geiss J. Gepirone treatment of generalized anxiety disorder (GAD). 50th NCDEU Annual Meeting, Boca Raton, FL, June 14-17, 2010.
23. Alpert JE, Franznick DA, Hollander SB, Fava M. Gepirone extended-release treatment of anxious depression: Evidence from a retrospective subgroup analysis in patients with major depressive disorder. J Clin Psychiatry 2004;65:1069-75.
24. Fabre LF, Brown CS, Smith LC, DeRogatis LR. Gepirone-ER treatment of hypoactive sexual desire disorder (HSDD) associated with depression in women. J Sex Med 2011;8:1411-9.
25. Fabre LF, Smith LC, DeRogatis LR. Gepirone-ER treatment of low sexual desire associated with depression in women as measured by the DeRogatis Inventory of Sexual Function (DISF) fantasy/cognition (desire) domain-A post hoc analysis. J Sex Med 2011;8:2569-81.
26. Hamilton M. A rating scale for depression. J Neurol Neurosurg Psychiatry 1960;23:56-62.
27. Camm AJ. The design and conduct of human studies to detect and quantify QT interval prolongation induced by new chemical entities. Fundam Clin Pharmacol 2002;16:141-5.
28. Clayton AH, McGarvey EL, Clavet GJ, Piazza L. Comparison of sexual functioning in clinical and nonclinical populations using the Changes in Sexual Functioning Questionnaire (CSFQ). Psychopharmacol Bull 1997;33:747-53.
29. Clayton AH, McGarvey EL, Clavet GJ. The Changes in Sexual Functioning Questionnaire (CSFQ): Development, reliability, and validity. Psychopharmacol Bull 1997;33:731-45.
30. Fabre LF, Smith LC. The effect of major depression on sexual function in women. J Sex Med 2011 Aug 30 [Epub ahead of print] doi: 10.1111/j.1743-6109.2011.02445.x.
31. Fabre LF, Smith LC, DeRogatis LR. The effect of depression on male sexual function. Fourteenth ISSM World Meeting, Seoul, South Korea, September 26-30, 2010.
32. Rosen RC, Cappelleri JC, Gendrano N 3rd. The International Index of Erectile Function (IIEF): A state-of-the-science review. Int J Impot Res 2002;14:226-44.
33. Goldstein I, Kim E, Steers WD, Pryor JL, Wilde DW, Natanegara F, Wong DG, Ahuja S. Efficacy and safety of tadalafil in men with erectile dysfunction with a high prevalence of comorbid conditions: Results from MOMENTUS: Multiple observations in men with erectile dysfunction in National Tadalafil Study in the US. J Sex Med 2007;4:166-75. Erratum in: J Sex Med 2007;4:522.
34. Amore M, Scarlatti F, Quarta AL, Tagariello P. Partial androgen deficiency, depression and testosterone treatment in aging men. Aging Clin Exp Res 2009;21:1-8.
35. Reynolds CF 3rd, Frank E, Thase ME, Houck PR, Jennings JR, Howell JR, Lilienfeld SO, Kupfer DJ. Assessment of sexual function in depressed, impotent, and healthy men: Factor analysis of a Brief Sexual Function Questionnaire for men. Psychiatry Res 1988;24:231-50.
36. Smith JF, Breyer BN, Eisenberg ML, Sharlip ID, Shindel AW. Sexual function and depressive symptoms among male North American medical students. J Sex Med 2010;7:3909-17.
37. Kennedy SH, Dickens SE, Eisfeld BS, Bagby RM. Sexual dysfunction before antidepressant therapy in major depression. J Affect Disord 1999;56:201-8.
38. Fossey MD, Hamner MB. Clonazepam-related sexual dysfunction in male veterans with PTSD. Anxiety 19941995;1:233-6.
39. Higgins A, Nash M, Lynch AM. Antidepressant-associated sexual dysfunction: Impact, effects, and treatment. Drug Healthc Patient Saf 2010;2:141-50.